Britain and America have forged a landmark trade agreement that will ensure no duties on UK drug exports going into the US market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to boost funding on drugs through the National Health Service (NHS). This move ensures that tariffs on these key exports will stay at nothing for a period of 36 months.
This deal is in response to earlier threats to significantly raise duties on branded pharmaceutical imports, with potential rates floated up to double the cost.
"This deal between the Britain bolsters the international landscape for innovative medicines and brings long-overdue balance to U.S.–U.K. drug exports," an announcement noted.
Trade Significance
Drugs represent one of the UK's most significant goods shipped to the America, which is clearly the largest destination for large UK drugmakers.
Statistics indicate that in the one-year period leading up to September, the UK exported medicines valued at £11.1bn to the US. This figure made up a significant portion of all goods exports in that timeframe.
"This guarantee secures jobs, increases investment and paves the way for the UK to establish itself as a global hub for life sciences," a minister commented.
Detailed British Pledges
The pact entails several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount drug companies must refund to the NHS to stay within budget will be limited at 15%. Last year, repayments topped twenty percent.
Industry Background
The deal follows a long-running row between the drug companies and the ministers over medicine costs and NHS adoption.
This friction were heightened by claims that US patients were charged significantly more for the identical medicines than patients in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been pledged toward US facilities.
A senior figure publicly accepted that the NHS must spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the previous ten-year period.
